VIVUS, Inc. (NASDAQ:VVUS) hit a new 52-week low on Thursday . The company traded as low as $2.53 and last traded at $2.59, with a volume of 2472 shares trading hands. The stock had previously closed at $2.60.

VVUS has been the subject of a number of recent analyst reports. ValuEngine upgraded shares of VIVUS from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research upgraded shares of VIVUS from a “sell” rating to a “hold” rating in a research report on Friday, August 24th.

The stock has a market cap of $27.00 million, a price-to-earnings ratio of -1.03 and a beta of 0.70.

VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.24. The company had revenue of $18.09 million for the quarter. On average, sell-side analysts predict that VIVUS, Inc. will post -3.59 earnings per share for the current fiscal year.

In other VIVUS news, CFO Mark K. Oki acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 6th. The stock was purchased at an average price of $4.07 per share, for a total transaction of $40,700.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $40,700. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.60% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in VIVUS stock. Worth Venture Partners LLC acquired a new stake in VIVUS, Inc. (NASDAQ:VVUS) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $132,000. Worth Venture Partners LLC owned approximately 0.28% of VIVUS as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.02% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “VIVUS (VVUS) Reaches New 12-Month Low at $2.53” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at


VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Featured Story: The Discount Rate – What You Need to Know

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.